Corcept Therapeutics | CORT - Equity Capital And Reserves


Corcept Therapeutics reported $637.99M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Alaunos Therapeutics USD 1.29M 865K Mar/2026
ANI Pharmaceuticals USD 562.3M 21.58M Mar/2026
Ardelyx USD 148.62M 18.33M Mar/2026
Aurora Cannabis CAD 511.83M 24.53M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Canopy Growth CAD 697.59M 60.58M Mar/2026
Corcept Therapeutics USD 637.99M 9.82M Mar/2026
Eli Lilly USD 31.2B 4.66B Mar/2026
J&J USD 81.19B 358M Mar/2026
Knight Therapeutics CAD 767.27M 480K Dec/2025
Lexicon Pharmaceuticals USD 202.86M 95.32M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Novartis USD 38.93B 7.2B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Omeros USD -228.68M 15.13M Jun/2025
Pacira USD 653.89M 39.22M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Supernus Pharmaceuticals USD 1.08B 15.09M Mar/2026
TG Therapeutics USD 583.13M 64.89M Mar/2026